Washington Magazine

Diabetes Pipeline Analysis

Diabetes Pipeline constitutes 200+ key companies continuously working towards developing 200+ Diabetes treatment therapies, analyzes DelveInsight.

Diabetes Overview:

Diabetes is a long-term metabolic disorder characterized by high blood sugar levels resulting from the body’s inability to produce enough insulin or use it effectively. Insulin is a key hormone that regulates glucose levels. The two primary forms are Type 1 diabetes, an autoimmune condition where the immune system destroys insulin-producing cells in the pancreas, and Type 2 diabetes, which is more prevalent and often associated with insulin resistance and lifestyle factors such as obesity and poor dietary habits. Additional types include gestational diabetes, which develops during pregnancy, and less common forms like Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).

Symptoms vary by type and severity but typically include excessive thirst, frequent urination, increased hunger, unintended weight loss, fatigue, and blurred vision due to unstable glucose levels. Type 2 diabetes may also involve slow-healing wounds, recurrent infections, and numbness or tingling in the extremities—signs of possible nerve damage.

Request for a detailed insights report on Diabetes pipeline insights

“Diabetes Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetes Therapeutics Market.

Key Takeaways from the Diabetes Pipeline Report

• DelveInsight’s Diabetes pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Diabetes treatment.

• In November 2025, GIOSTAR announced that it received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial for the development of a targeted stem cell therapy for Type II Diabetes.

• In January 2025, Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India for the first time.

• Key Diabetes companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others are evaluating new drugs for Diabetes to improve the treatment landscape.

• Promising Diabetes pipeline therapies in various stages of development include Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others.

Diabetes Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Diabetes Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetes market.

Download our free sample page report on Diabetes pipeline insights

Diabetes Emerging Drugs

• Cadisegliatin: vTv Therapeutics

• LY-3209590: Eli Lilly and Company

• THDB0206: Tonghua Dongbao Pharmaceutical

• CPL207280: Celon Pharma

• XW014: Sciwind Biosciences

• KN056: Suzhou Alphamab Co., Ltd.

Diabetes Companies

More than 200 prominent companies are actively involved in developing diabetes treatments. Among these, vTv Therapeutics, Eli Lilly and Company, and Tonghua Dongbao Pharmaceutical have drug candidates that have progressed to the most advanced stage—Phase III clinical trials.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Diabetes Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetes Therapies and Key Companies: Diabetes Clinical Trials and advancements

Diabetes Pipeline Therapeutic Assessment

• Diabetes Assessment by Product Type

• Diabetes By Stage

• Diabetes Assessment by Route of Administration

• Diabetes Assessment by Molecule Type

Download Diabetes Sample report to know in detail about the Diabetes treatment market @ Diabetes Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Diabetes Current Treatment Patterns

4. Diabetes – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetes Late-Stage Products (Phase-III)

7. Diabetes Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetes Discontinued Products

13. Diabetes Product Profiles

14. Diabetes Key Companies

15. Diabetes Key Products

16. Dormant and Discontinued Products

17. Diabetes Unmet Needs

18. Diabetes Future Perspectives

19. Diabetes Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights Diabetes Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/